2-(diethylamino)ethyl iodide | 242151-48-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(diethylamino)ethyl iodide
• 英文别名: diethyl-(2-iodo-ethyl)-amine；1-Diaethylamino-2-jod-aethan；Diaethyl-(2-jod-aethyl)-amin；2-Jod-triaethylamin；Diaethyl-(β-jod-aethyl)-amin；Diethyl(2-iodoethyl)amine；N,N-diethyl-2-iodoethanamine
• CAS: 242151-48-0
• 化学式: C₆H₁₄IN
• 分子量: 227.088
• InChiKey: WYHOFOZPBHOEGE-UHFFFAOYSA-N

物化性质

• 沸点：
  183.3±23.0 °C(Predicted)
• 密度：
  1.477±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(diethylamino)ethyl iodide 在 sodium hydroxide 、 potassium carbonate 作用下， 以 乙醇 为溶剂， 生成 2-(benzhydrylamino)oxy-N,N-diethylethanamine
  参考文献：
  名称：

  Bellasio; Parravicini; La Noce, Farmaco, Edizione Scientifica, 1968, vol. 23, # 4, p. 372 - 382

  摘要：

  DOI：
• 作为产物：
  描述：

  2-二乙氨基氯乙烷盐酸盐 在 乙醇 、 sodium iodide 作用下， 生成 2-(diethylamino)ethyl iodide
  参考文献：
  名称：

  GB368590

  摘要：

  公开号：

文献信息

• Inhibitors of VEGF receptor and HGF receptor signaling
  申请人：Saavedra Mario Oscar

  公开号：US20070004675A1

  公开（公告）日：2007-01-04

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  该发明涉及抑制VEGF受体信号和HGF受体信号。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
• Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling
  作者：Thota Ganesh、Jaeki Min、Pahk Thepchatri、Yuhong Du、Lian Li、Iestyn Lewis、Larry Wilson、Haian Fu、Gabriela Chiosis、Raymond Dingledine、Dennis Liotta、James P. Snyder、Aiming Sun

  DOI：10.1016/j.bmc.2008.05.047

  日期：2008.7

  The molecular chaperone Hsp90 plays important roles in maintaining malignant phenotypes. Recent studies suggest that Hsp90 exerts high-affinity interactions with multiple oncoproteins, which are essential for the growth of tumor cells. As a result, research has focused on finding Hsp90 probes as potential and selective anticancer agents. In a high-throughput screening exercise, we identified quinoline

  分子伴侣 Hsp90 在维持恶性表型中起重要作用。最近的研究表明，Hsp90 与多种癌蛋白产生高亲和力相互作用，这对肿瘤细胞的生长至关重要。因此，研究的重点是寻找 Hsp90 探针作为潜在和选择性的抗癌剂。在高通量筛选练习中，我们将喹啉 7 鉴定为 Hsp90 的中度抑制剂。进一步的命中识别、SAR 研究和生物学调查揭示了该系列中的几种合成类似物在荧光偏振 (FP) 测定和基于细胞的蛋白质印迹 (WB) 测定中均具有微摩尔活性。这些化合物代表了一类具有简单化学结构的新型 Hsp90 抑制剂。
• INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING
  申请人：Saavedra Oscar Mario

  公开号：US20120083482A1

  公开（公告）日：2012-04-05

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds of general formula (A) wherein A 1 is sulfur, A 3 is CH, A 2 is CH, D is heterocycle, Z is oxygen, SO 0-2 or NR, Ar is phenyl and G is not a ring, and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制VEGF受体信号和HGF受体信号的技术。本发明提供了通式（A）的化合物，其中A1为硫，A3为CH，A2为CH，D为杂环，Z为氧，SO0-2或NR，Ar为苯基，G不是环，并提供了抑制VEGF受体信号和HGF受体信号的方法。本发明还提供了治疗细胞增殖性疾病和病情的组合物和方法。
• MICELLE CONTAINING EPIRUBICIN-COMPLEXED BLOCK COPOLYMER AND ANTI-CANCER AGENT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAID MICELLE APPLICABLE TO TREATMENT OF CANCER, RESISTANT CANCER OR METASTATIC CANCER
  申请人：The University of Tokyo

  公开号：EP3181136A1

  公开（公告）日：2017-06-21

  The problem addressed by the present invention is to develop a pharmaceutical having therapeutic efficacy against epirubicin-resistant tumors. The present invention provides a micelle having an anti-cancer agent disposed inside the core of the micelle formed by an epirubicin-conjugated copolymer.

  本发明所要解决的问题是开发一种对表柔比星耐药性肿瘤具有疗效的药物。本发明提供了一种胶束，其抗癌剂被置于由表柔比星共聚物形成的胶束核心内。
• URACIL COMPOUND AS C-MET/AXL INHIBITOR
  申请人：Medshine Discovery Inc.

  公开号：EP3719012A1

  公开（公告）日：2020-10-07

  Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor.

  本发明提供了一种由式（IV）代表的尿嘧啶化合物或其药学上可接受的盐及其药物组合物。还提供了其作为 c-MET/AXL 抑制剂在制备 c-MET/AXL 抑制药物或治疗肿瘤药物中的用途。